Of the 135 patients who listed at least one side effect, loss of appetite, sleep problems (typically difficulty falling asleep), and mood disturbance (often mood swings) were most frequently reported by patients. Figure 1 displays the most commonly mentioned side effects. Data on side effects were tabulated for patients taking one of the following attention deficit hyperactivity disorder (ADHD) medications: amphetamine and dextroamphetamine atomoxetine dexmethylphenidate lisdexamfetamine and methylphenidate.įorty-eight percent of the approximately 325 members surveyed experienced a side effect as a result of taking an ADHD medication. , a medication monitoring service, randomly surveys enrolled members on a continuous basis to obtain data on treatment satisfaction, efficacy, and side effects using a validated patient-reported outcomes instrument called the Treatment Satisfaction Questionnaire for Medications (TSQM). In this article, we provide information on patient-reported side effects from a cross-section of real-world patients. Recognizing that time for patient care is limited, it is important for practicing physicians to understand which issues to prioritize in their patient interactions. Regardless of how bothersome the side effects were, only 20 percent of patients mentioned the side effects to their prescribing physicians. Only 21 percent of side effects were considered very bothersome or extremely bothersome. Most common side effects mentioned included loss of appetite, sleep problems, and mood disturbances.
Forty-eight percent of the approximately 325 patients surveyed reported having experienced a side effect as a result of taking an attention deficit hyperactivity disorder medication. Specifically, data on side effects were tabulated for patients taking one of the following attention deficit hyperactivity disorder medications: amphetamine and dextroamphetamine atomoxetine dexmethylphenidate lisdexamfetamine and methylphenidate. Key words: Attention deficit hyperactivity disorder, ADHD, side effect, patient-reported side effect, amphetamine, dextroamphetamine, atomoxetine dexmethylphenidate, lisdexamfetamine, methylphenidate Wigal served on the advisory board, consulted to, received research support from, or been on the speaker’s bureau of the following: Addrenex, Eli Lilly and Company, McNeil Consumer & Specialty Pharmaceuticals, Next Wave Pharm., NIMH, Shionogi Pharma, Shire US Inc., and TAISHO. Kalali have no conflicts of interest relevant to the content of this article. Wigal is Clinical Professor of Pediatrics University of California Irvine Director of Clinical Trials, Child Development Center, Irvine, California.įunding: There was no funding for the development and writing of this article.įinancial disclosures: Ms.
Kalali is Vice President, Global Therapeutic Group Leader CNS, Quintiles, Inc., and Professor of Psychiatry, University of California, San Diego, California and Dr. Cascade is Vice President, Quintiles Inc./iGuard, Falls Church, Virginia Dr.
0 kommentar(er)
